CRISPR Therapeutics Reports Durable CTX310 Lipid Lowering
Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...
LDL cholesterol
Advertisement
Amgen’s Repatha Wins CHMP Support for Broader Heart Protection
THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...
NewAmsterdam Pharma Wins CHMP Support for Ubeslo® and Evlarco®
NAARDEN, The Netherlands; MIAMI, USA; and FLORENCE, Italy, July 24, 2026 NewAmsterdam Pharma and its commercialization partner Menarini Group...
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data
NAARDEN, the Netherlands & MIAMI, July 1, 2026 NewAmsterdam Pharma Company N.V. announced that it will present multiple clinical...
Chiesi Wins EU Approval for Pediatric LOJUXTA Use
PARMA, Italy, June 5, 2026 Chiesi Global Rare Diseases has announced a major regulatory milestone following the European Commission’s...
Advertisements
Lilly’s VERVE-102 Shows Durable LDL-C Reduction
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
AIRNA Showcases RNA Editing Advances at ASGCT 2026
CAMBRIDGE, Mass., May 12, 2026 AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell...
Merck Publishes Science Paper on Scalable Oral PCSK9 Inhibitor Manufacturing
RAHWAY, N.J., May 7, 2026 Merck announced the publication of a landmark scientific paper in the journal Science detailing...
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Advertisement
